Soleo Health to distribute Pasatru through its rare disease business
Also Noted
By HME News Staff
Updated 10:25 AM CST, Wed November 11, 2026
FRISCO, Texas — Soleo Health has been selected as a specialty pharmacy partner for Regeneron’s Pasatru (garetosmab-grts), which received approval from the U.S. Food and Drug Administration in August. The therapy reduces formation of new heterotopic ossification (HO) lesions and clinician-assessed flare-ups in adults with fibrodysplasia ossificans progressiva (FOP), an ultra-rare genetic disorder. “The addition of Pasatru to SoleoRare, our Rare Disease Specialty Pharmacy, underscores our commitment to bringing specialized care to the FOP community,” said Drew Walk, CEO of Soleo Health. “We are pleased to be one of two select partners working with Regeneron to support the availability of this novel treatment and apply our rare disease expertise to help patients receive exceptional care.” Soleo Health will assist eligible patients gain access to Pasatru by working with providers, patient assistance programs, and infusion support. Through its experienced Soleo-employed nurses and clinical support team, the company will leverage its ultra-rare disease expertise to help streamline coordination of therapy.
Related: Soleo launched SoleoRare in April to better serve patients with rare diseases.